<DOC>
	<DOCNO>NCT01337596</DOCNO>
	<brief_summary>To evaluate safety tolerability LY2951742 give single multiple subcutaneous injection healthy male subject</brief_summary>
	<brief_title>A Study LY2951742 Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Are healthy Caucasian male , determine medical history physical examination Agree use reliable method birth control ( e.g . condom AND additional contraception method use respective partner ) study 3 month follow last dose investigational product Have body mass index ( BMI ) great 19 kilogram/square meter ( kg/m^2 ) Have clinical laboratory test result within normal reference range population investigator site Have venous access sufficient allow blood sampling Are willing follow study procedure include drug ( exception study drug ) 72 hour prior initiation laser doppler imaging ( LDI ) procedure , chocolate , alcohol caffeine containing product 12 hour prior initiation laser doppler imaging ( LDI ) procedure , complete 4 hour fast prior initiation laser doppler imaging ( LDI ) procedure Have suitable skin characteristic dermal capsaicin challenge demonstrate 100 percent increase dermal flow follow capsaicin challenge part screening procedure measure laser doppler imaging ( LDI ) Are currently enrol , complete discontinue within last 30 day , clinical trial involve investigational product ; concurrently enrol type medical research judge scientifically medically compatible study Are persons previously receive investigational product study , complete withdrawn study investigate LY2951742 Have abnormality 12lead electrocardiogram ( ECG ) , opinion investigator , increase risk associate participate study include QTc great 450 millisecond ( msec ) ( male ) , history congenital long QT syndrome conduction abnormality Have abnormal vital sign determine investigator Have history presence significant cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , hematological , neurological disorder ( include migraine ) would constitute risk take study medication ; interfere interpretation data study Regularly use know drug abuse and/or show positive finding urinary drug screen Show evidence : 1 . Human immunodeficiency virus infection and/or positive human immunodeficiency virus ( HIV ) antibodies 2 . Hepatitis C and/or positive hepatitis C antibody 3 . Hepatitis B and/or positive hepatitis B surface antigen Intend use overthecounter prescription medication may interfere study safety assessment measurement within 7 day prior dose study ( example : systemic glucocorticoid , immunomodulatory drug , drug propensity dermal reaction , drug know liver toxicity ) . Have donate blood 500 milliliter ( mL ) undergone major surgery The use caffeine containing product alcohol allow 12 hour prior study visit clinic stay . All time , alcohol consumption caffeine intake limit 2 alcoholic beverage equivalent ( beer [ 284 mL/10 ounce ] , wine [ 125 mL/4 ounce ] , distilled spirit ( 25 milliliter [ mL/1 ounce ] ) per day caffeinated beverage limit 2 unit per day amount ( 1 unit=120 milligram [ mg ] caffeine ) . Strenuous activity allow 1 week prior admission followup visit . Are smoker within previous 6 month Have receive treatment biologic agent ( monoclonal antibody ) within 3 month 5 halflives ( whichever longer ) prior dose receive vaccination within 1 month Have history multiple severe allergy anaphylactic reaction intolerability prescription nonprescription drug food Are immunocompromised Have cancer within past 5 year Have history significant allergy , particular ethanol sensitivity fruit capsicum plant ( example : chili pepper ) Have eczema , scleroderma , psoriasis , dermatitis , keloid , tumor , ulcer , burn , flap , graft forearm abnormality skin may interfere study assessment Can avoid excess tanning ( exposure sunlight tan bed would cause sunburn reaction ) throughout study cover forearm 24 hour prior treatment period Have excessive hair growth volar surface forearm subject currently use lotion , oil , depilatory preparation , topical treatment regular basis discontinue duration study ; subject use topical treatment within 7 day start study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>pain</keyword>
	<keyword>neuropathic pain</keyword>
	<keyword>headache</keyword>
</DOC>